Renae M. Ryan

Renae M. Ryan

Auto-generated profile, based on publicly available information

Renae M. Ryan

School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2007 in Nature
Verified
Journal Article
Closed access
PDF file
OBOlga Boudker
Olga Boudker
RRRenae M. Ryan
Renae M. Ryan
DYDinesh Yernool
Dinesh Yernool
KSKeiko Shimamoto
Keiko Shimamoto
EGEric Gouaux
Eric Gouaux

1 October 2013 in Physiological Reviews
Verified
Journal Article
Open access
PDF file
Robert VandenbergRobert Vandenberg
Robert Vandenberg
RRRenae M. Ryan
Renae M. Ryan
L-Glutamate is the predominant excitatory neurotransmitter in the mammalian central nervous system and plays important roles in a wide variety of brain functions, but it is also a key player in the pathogenesis of many neurological disorders. The control of glutamate concentrations is critical to the normal functioning of the central nervous system, and in this review we discuss how glutamate transporters regulate glutamate concentrations to maintain dynamic signaling mechanisms between neurons. In 2004, the crystal structure of a prokaryotic homolog of the mammalian glutamate transporter family of proteins was crystallized and its structure determined. This has paved the way for a better understanding of the structural basis for glutamate transporter function. In this review we provide a broad perspective of this field of research, but focus primarily on the more recent studies with a particular emphasis on how our understanding of the structure of glutamate transporters has generated new insights.

17 February 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
QWQian Wang
Qian Wang
KBKimberley A. Beaumont
Kimberley A. Beaumont
NONicholas J. Otte
Nicholas J. Otte
JFJosep Font
Josep Font
Charles BaileyCharles Bailey
Charles Bailey
JHJeff Holst
Jeff Holst
Amino acids, especially leucine and glutamine, are important for tumor cell growth, survival and metabolism. A range of different transporters deliver each specific amino acid into cells, some of which are increased in cancer. These amino acids consequently activate the mTORC1 pathway and drive cell cycle progression. The leucine transporter LAT1/4F2hc heterodimer assembles as part of a large complex with the glutamine transporter ASCT2 to transport amino acids. In this study, we show that the expression of LAT1 and ASCT2 is significantly increased in human melanoma samples and is present in both BRAFWT (C8161 and WM852) and BRAFV600E mutant (1205Lu and 451Lu) melanoma cell lines. While inhibition of LAT1 by BCH did not suppress melanoma cell growth, the ASCT2 inhibitor BenSer significantly reduced both leucine and glutamine transport in melanoma cells, leading to inhibition of mTORC1 signaling. Cell proliferation and cell cycle progression were significantly reduced in the presence of BenSer in melanoma cells in 2D and 3D cell culture. This included reduced expression of the cell cycle regulators CDK1 and UBE2C. The importance of ASCT2 expression in melanoma was confirmed by shRNA knockdown, which inhibited glutamine uptake, mTORC1 signaling and cell proliferation. Taken together, our study demonstrates that ASCT2‐mediated glutamine transport is a potential therapeutic target for both BRAFWT and BRAFV600E melanoma.

4 January 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Charles BaileyCharles Bailey
Charles Bailey
RRRenae M. Ryan
Renae M. Ryan
ATAnnora D. Thoeng
Annora D. Thoeng
CNCynthia Ng
Cynthia Ng
KKKara King
Kara King
JRJohn E.J. Rasko
John E.J. Rasko
Solute carrier family 1, member 1 (SLC1A1; also known as EAAT3 and EAAC1) is the major epithelial transporter of glutamate and aspartate in the kidneys and intestines of rodents. Within the brain, SLC1A1 serves as the predominant neuronal glutamate transporter and buffers the synaptic release of the excitatory neurotransmitter glutamate within the interneuronal synaptic cleft. Recent studies have also revealed that polymorphisms in SLC1A1 are associated with obsessive-compulsive disorder (OCD) in early-onset patient cohorts. Here we report that SLC1A1 mutations leading to substitution of arginine to tryptophan at position 445 (R445W) and deletion of isoleucine at position 395 (I395del) cause human dicarboxylic aminoaciduria, an autosomal recessive disorder of urinary glutamate and aspartate transport that can be associated with mental retardation. These mutations of conserved residues impeded or abrogated glutamate and cysteine transport by SLC1A1 and led to near-absent surface expression in a canine kidney cell line. These findings provide evidence that SLC1A1 is the major renal transporter of glutamate and aspartate in humans and implicate SLC1A1 in the pathogenesis of some neurological disorders.

1 June 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RRRenae M. Ryan
Renae M. Ryan
ECEmma L.R. Compton
Emma L.R. Compton
JMJoseph A. Mindell
Joseph A. Mindell
Excitatory amino acid transporters (EAATs) are crucial in maintaining extracellular levels of glutamate, the most abundant excitatory neurotransmitter, below toxic levels. The recent three-dimensional crystal structure of GltPh, an archaeal homolog of the EAATs, provides elegant structural details of this family of proteins, yet we know little about the mechanism of the bacterial transporter. Conflicting reports in the literature have described GltPh as an aspartate transporter driven by Na+ or a glutamate transporter driven by either Na+ or H+. Here we use purified protein reconstituted into liposomes to thoroughly characterize the ion and substrate dependence of the GltPh transport. We confirm that GltPh is a Na+-dependent transporter that is highly selective for aspartate over other amino acids, and we show that transport is coupled to at least two Na+ ions. In contrast to the EAATs, transport via GltPh is independent of H+ and K+. We propose a kinetic model of transport in which at least two Na+ ions are coupled to the cotransport of each aspartate molecule by GltPh, and where an ion- and substrate-free transporter reorients to complete the transport cycle.

15 April 2007 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
RRRenae M Ryan
Renae M Ryan
JMJoseph A Mindell
Joseph A Mindell